David Zarling

David A. Zarling, PhD, MBA
Occupation(s)	CEO, Colby Pharmaceutical Company

David A. Zarling,PhD, MBA is a co-founder, president and CEO of Colby Pharmaceutical Company.

David A. Zarling has many years experience in start-up executive management and oncology drug development as an entrepreneur. He has expertise in product development, licensing transactions, finance, collaborations and partnering. Previously, he was the Executive Vice President and was subsequently promoted to President and CEO of Pangene Corporation (PGC, Mt View, CA), a service company which provided drug and drug target development services in Pharmaceuticals, Genomics & Cancer. Pangene was formed within and spun-out from SRI International, formerly Stanford Research Institute, Menlo Park, CA. David co-founded PGC as a spin-out company from SRI International’s Pharmaceutical Drug Development/Genomics/Cancer Programs in the SRI Life Sciences Division, where he was a manager and program director. PGC sold Pharmaceutical/Genomics/ Cancer target bio-validation services to pharma and biotech companies and achieved significant revenues. The PGC drug and target bio-validation assets, services and clients were partnered and sold as a profitable business. At SRI, and in collaboration with the SRI wholly owned for profit subsidiary, Sarnoff Corporation, David helped organize, secure funding for and co-led a biotechnology platform based product development group. This group was responsible for significant new business and product development, including IP and product candidates, which were successfully out-licensed. This included the team’s development of genomics technology which spun out of SRI with the PGC start-up where David as Executive Vice President.

Prior to this, David was employed at SRI International as a Program Director in the Pharmaceutical Drug Development Division, where he led a team which developed drug targets, oncology drug candidates and development of companion diagnostic product candidates. Some of these were developed for public international companies and others were out-licensed to public and private companies. At SRI, he also managed contract research for pharmaceutical and biotech companies and worked in drug development and consulting teams for domestic and international Pharma and Biotech companies. He led or was part of drug and associated companion diagnostic product development teams transitioning pre-clinical small molecule drugs into the clinic and he performed his doctoral work on small molecule anti-cancer drugs.

David was also an Associate Adjunct Professor at the University of California San Francisco and has had several successful collaborations with clinical and pre-clinical investigators at major cancer and other research centers. He also has numerous peer-reviewed scientific publications, many issued US and Foreign patents and a deal sheet record for responsive and successful deals. David Zarling also has been a part of teams that successfully licensed technology to start-up companies, one of which subsequently achieved significant market capitalization . David was a S. L. Brown Scholar and holds a BA with Honors in Biology, a MA in Molecular Biology/ Biological Sciences from Dartmouth College, a Ph.D. in Virology/Oncology, with emphasis on pharmaceutical drug development, from Baylor College of Medicine and an Executive MBA in Marketing/Finance from Pepperdine University.

See also

• Reactive Oxygen Species
• Oxidative Stress
• Prostate Cancer
• Benign Prostatic Hyperplasia

External links

• Colby Pharmaceutical Company Website
• SRI International
• David Zarling at GTCbio's 5th Annual Cancer Drugs R&D Conference
• Profile of CPC and interview with David Zarling at Onemedplace

Selected Publications

• New radiosensitizing regimens, drugs, prodrugs, and candidates., Vallerga AK, Zarling DA, Kinsella TJ., Clin Adv Hematol Oncol. 2004 Dec;2(12):793-805

• Analysis of a one-dimensional random walk with irreversible losses at each step: applications for protein movement on DNA. Belotserkovskii BP, Zarling DA., J Theor Biol. 2004 Jan 21;226(2):195-203

• efficiency of transgenic livestock production. Marga et al, Transgenic Res. 2003 Aug;12(4):485-96

• Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Taverna et al, Cancer Res. 2003 Feb 15;63(4):838-46

• Discovery of gene families and alternatively spliced variants by RecA-mediated cloning. Zeng H, Allen E, Lehman CW, Sargent RG, Pati S, Zarling DA., Genomics. 2002 Nov;80(5):543-51
• Peptide nucleic acid (PNA) facilitates multistranded hybrid formation between linear double-stranded DNA targets and RecA protein-coated complementary single-stranded DNA probes. Belotserkovskii BP, Zarling DA. Biochemistry. 2002 Mar 19;41(11):3686-92